Developer docs
API playgroundTry for free, no card

Search company profiles

Stelis Biopharma

Full company profile

uuid005dlcs

Namestring
Stelis Biopharma
Legal namestring
OneSource
Websiteurl
stelis.com
Company typeenum
Private
Founded yearstring
-
Descriptiontext

OneSource (the operating brand of Stelis Biopharma) is a Bangalore, India-headquartered multimodal pharmaceutical Contract Development and Manufacturing Organization (CDMO) that delivers end-to-end services spanning process development, technology transfer, scale-up, and commercial manufacturing. It positions itself as a single-contract alternative to multi-vendor outsourcing models, with the explicit value proposition of reducing operational interfaces for pharmaceutical and biologics sponsors.

The portfolio rests on four core capability pillars: Drug-Device Combinations (over 20 automatic and semi-automatic flexible assembly stations supporting prefilled syringes, dial-and-push variable and fixed-dose pen injectors, pull-push fixed-dose pens, and autoinjectors); Sterile Injectables (35 approved US ANDAs, 19 commercialized US drug products, and capabilities across sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections); Complex Biologics (integrated process and analytics development with dedicated tech-transfer and scale-up resources); and Soft Gelatin Capsules (capacity of up to 2.4 billion capsules annually in multiple formats, shapes and sizes). Operations are consolidated in one state-of-the-art, multi-regulatory-body-approved facility, supported by 23+ scientists and techno-commercial leaders with seven years of operational and regulatory compliance track record.

Commercially, the business runs on an enterprise field-sales motion targeting pharmaceutical and biologics developers seeking complex dosage-form manufacturing, with a horizontal segmentation approach across use cases rather than therapeutic areas. Pricing is not publicly disclosed and is project/quote-based, consistent with CDMO contracting norms. The company maintains an investor-relations function including financial reports, stock-exchange intimation, and disclosures under Regulation 46 LODR, alongside active reference to two successive Schemes of Arrangement (2024 and 2025), signaling ongoing corporate restructuring. Distribution and demand generation mix a capabilities-focused website, conference participation (notably CPHI Frankfurt 2025), and direct enterprise outreach — with no named customers, channel partners, or distributor network disclosed in the available material.

Short descriptiontext

OneSource (Stelis Biopharma) is a Bangalore-based multimodal pharmaceutical CDMO offering end-to-end drug development and manufacturing across drug-device combinations, sterile injectables, complex biologics, and soft gelatin capsules for pharmaceutical and biologics sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersNot specified in source, India
HQ citystring
Not specified in source
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, biologics development services, sterile injectables manufacturing, drug-device combination products, soft gelatin capsule production
Industry6 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAKAA
Biologic API/Drug Substance Manufacturing Services
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeOthers
Description

As a CDMO, OneSource generates revenue through contract development and manufacturing services for pharmaceutical and biologics products, providing end-to-end solutions from development to commercialization.

onesourcecdmo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Stelis Biopharma, operating through its brand OneSource, is a multimodal specialty pharmaceutical and biologics Contract Development and Manufacturing Organization (CDMO) delivering end-to-end drug development and manufacturing across four capability platforms: drug-device combinations (prefilled syringes, pen injectors, autoinjectors), sterile injectables (liquids, lyophilized vials, prefilled syringes, dry powder injections), complex biologics (process and analytics development, tech transfer and scale-ups), and soft gelatin capsules (up to 2.4 billion capsules annually). Services are delivered under a single-contract model from one state-of-the-art, regulatory-approved facility to reduce clients' operational interfaces across the product lifecycle.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 35 approved Abbreviated New Drug Applications (ANDAs) in the United States
+3 more records
Product overview1 text field

OneSource is a multimodal specialty pharma CDMO (Contract Development and Manufacturing Organization) offering end-to-end capabilities across tech platforms and therapeutic modalities. The portfolio consists of four core service/product areas: Drug-Device Combinations (with flexible assembly stations for prefilled syringes and pen injectors), Sterile Injectables (with 35 approved ANDAs and 19 commercialized products), Complex Biologics (integrated process and analytics development), and Soft Gelatin Capsules (producing up to 2.4 billion capsules annually). These offerings are unified under a single contract model to provide comprehensive drug development and manufacturing solutions.

Product and service4 records
1Drug-Device Combinations
CategoryDrug-device combination contract manufacturing
Description

Contract manufacturing services for drug-device combination products, including prefilled syringes, dial-and-push variable and fixed dose pen injectors, pull-push fixed dose pens, and autoinjectors, supported by over 20 automatic and semi-automatic flexible assembly stations and tailored to client-specified device formats.

2Sterile Injectables
CategorySterile injectable contract manufacturing
Description

Contract development and manufacturing of complex sterile injectable drug products in multiple dosage forms, including sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections, backed by 35 approved ANDAs and 19 commercialized drug products in the United States.

3Complex Biologics
CategoryBiologics contract development and manufacturing
Description

Integrated contract development solutions for complex biologics combining flexible infrastructure, advanced technologies, and extensive capacity with process and analytics development and a dedicated team for tech transfer and scale-ups.

4Soft Gelatin Capsules
CategorySoft gelatin capsule contract manufacturing
Description

High-volume contract manufacturing of soft gelatin capsules producing up to 2.4 billion capsules annually in multiple formats and various shapes and sizes, using rapid and efficient production processes for high-quality softgel products.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

India-headquartered CDMO offering sterile injectables, drug-device combinations, and biologics manufacturing with global regulatory footprint. Closely comparable to OneSource in modality mix, customer base (US generic and innovator sponsors), and integrated CDMO positioning.

TypeBroad incumbent
Description

South Korea-based pure-play biologics CDMO with very large single-site mammalian cell culture capacity. Comparable in biologics CDMO segment and as a major single-facility operator, though focused exclusively on biologics rather than OneSource's multimodal mix.

TypeRegional player
Description

India-based vertically integrated generic pharma manufacturer with significant US ANDA approvals and injectable manufacturing. Comparable as a domestic competitor with similar US generic commercialized product footprint, though primarily a product company rather than pure CDMO.

4Syngene International
TypeDirect peer
Description

Bengaluru-based contract research, development and manufacturing organization serving global pharma with biologics manufacturing capabilities. Comparable as an India-headquartered, publicly listed CDMO with similar enterprise customer base.

TypeBroad incumbent
Description

Swiss-based global CDMO leader in biologics, cell and gene therapy, and small molecule manufacturing. Comparable as a broad incumbent with overlapping biologics and fill-finish capabilities, though at much larger scale and across multiple sites.

TypeBroad incumbent
Description

China-based global CRO/CDMO with substantial small molecule, biologics, and sterile injectable capacity. Comparable as a broad incumbent in integrated CDMO services, though operating at significantly larger scale.

TypeDirect peer
Description

Indian integrated pharma and CDMO with sterile injectables, APIs, and biologics capabilities. Comparable as a domestic competitor in similar dosage forms and end-to-end development-to-commercial services for global sponsors.

TypeBroad incumbent
Description

Global CDMO leader in softgel, sterile injectables, and drug-device combinations, now owned by Novo Holdings. Comparable as a broader incumbent offering many of the same modalities at significantly larger scale across multiple geographies.

TypeDirect peer
Description

Indian CDMO focused on complex APIs and contract development/manufacturing for global pharma. Comparable as an India-based, publicly listed mid-sized CDMO serving innovator and generic sponsors with regulated manufacturing capabilities.

TypeDirect peer
Description

India-based CDMO specializing in APIs and peptide manufacturing with US FDA-approved facilities. Comparable as a smaller Indian publicly listed CDMO competing for similar pharma sponsor outsourcing contracts.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stelis Biopharma

Pharmaceutical CDMO Servicesstelis.com

OneSource (Stelis Biopharma) is a Bangalore-based multimodal pharmaceutical CDMO offering end-to-end drug development and manufacturing across drug-device combinations, sterile injectables, complex biologics, and soft gelatin capsules for pharmaceutical and biologics sponsors.

What Stelis Biopharma does

OneSource (the operating brand of Stelis Biopharma) is a Bangalore, India-headquartered multimodal pharmaceutical Contract Development and Manufacturing Organization (CDMO) that delivers end-to-end services spanning process development, technology transfer, scale-up, and commercial manufacturing. It positions itself as a single-contract alternative to multi-vendor outsourcing models, with the explicit value proposition of reducing operational interfaces for pharmaceutical and biologics sponsors.

The portfolio rests on four core capability pillars: Drug-Device Combinations (over 20 automatic and semi-automatic flexible assembly stations supporting prefilled syringes, dial-and-push variable and fixed-dose pen injectors, pull-push fixed-dose pens, and autoinjectors); Sterile Injectables (35 approved US ANDAs, 19 commercialized US drug products, and capabilities across sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections); Complex Biologics (integrated process and analytics development with dedicated tech-transfer and scale-up resources); and Soft Gelatin Capsules (capacity of up to 2.4 billion capsules annually in multiple formats, shapes and sizes). Operations are consolidated in one state-of-the-art, multi-regulatory-body-approved facility, supported by 23+ scientists and techno-commercial leaders with seven years of operational and regulatory compliance track record.

Commercially, the business runs on an enterprise field-sales motion targeting pharmaceutical and biologics developers seeking complex dosage-form manufacturing, with a horizontal segmentation approach across use cases rather than therapeutic areas. Pricing is not publicly disclosed and is project/quote-based, consistent with CDMO contracting norms. The company maintains an investor-relations function including financial reports, stock-exchange intimation, and disclosures under Regulation 46 LODR, alongside active reference to two successive Schemes of Arrangement (2024 and 2025), signaling ongoing corporate restructuring. Distribution and demand generation mix a capabilities-focused website, conference participation (notably CPHI Frankfurt 2025), and direct enterprise outreach — with no named customers, channel partners, or distributor network disclosed in the available material.

Stelis Biopharma firmographics

Firmographics
Name
Stelis Biopharma
Legal name
OneSource
Website
https://stelis.com
Company type
Private
Operating status
Operating
Headcount range
251–500 employees
Short description
OneSource (Stelis Biopharma) is a Bangalore-based multimodal pharmaceutical CDMO offering end-to-end drug development and manufacturing across drug-device combinations, sterile injectables, complex biologics, and soft gelatin capsules for pharmaceutical and biologics sponsors.
Ownership category
akta.pro rank

Stelis Biopharma industry classification

Industry
Product category
Pharmaceutical CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAKAA
Biologic API/Drug Substance Manufacturing Services
SECONDARYHLAAAJAG
Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)

Keywords

  • Contract pharmaceutical manufacturing
  • Biologics development services
  • Sterile injectables manufacturing
  • Drug-device combination products
  • Soft gelatin capsule production

Where Stelis Biopharma is headquartered

Location

Headquarters

HQ city
Not specified in source
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Stelis Biopharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: As a CDMO, OneSource generates revenue through contract development and manufacturing services for pharmaceutical and biologics products, providing end-to-end solutions from development to commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Stelis Biopharma product offering

Product offering

Core offering

Stelis Biopharma, operating through its brand OneSource, is a multimodal specialty pharmaceutical and biologics Contract Development and Manufacturing Organization (CDMO) delivering end-to-end drug development and manufacturing across four capability platforms: drug-device combinations (prefilled syringes, pen injectors, autoinjectors), sterile injectables (liquids, lyophilized vials, prefilled syringes, dry powder injections), complex biologics (process and analytics development, tech transfer and scale-ups), and soft gelatin capsules (up to 2.4 billion capsules annually). Services are delivered under a single-contract model from one state-of-the-art, regulatory-approved facility to reduce clients' operational interfaces across the product lifecycle.

Product overview

OneSource is a multimodal specialty pharma CDMO (Contract Development and Manufacturing Organization) offering end-to-end capabilities across tech platforms and therapeutic modalities. The portfolio consists of four core service/product areas: Drug-Device Combinations (with flexible assembly stations for prefilled syringes and pen injectors), Sterile Injectables (with 35 approved ANDAs and 19 commercialized products), Complex Biologics (integrated process and analytics development), and Soft Gelatin Capsules (producing up to 2.4 billion capsules annually). These offerings are unified under a single contract model to provide comprehensive drug development and manufacturing solutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug-Device Combinations Contract manufacturing services for drug-device combination products, including prefilled syringes, dial-and-push variable and fixed dose pen injectors, pull-push fixed dose pens, and autoinjectors, supported by over 20 automatic and semi-automatic flexible assembly stations and tailored to client-specified device formats.
  • Sterile Injectables Contract development and manufacturing of complex sterile injectable drug products in multiple dosage forms, including sterile liquids, lyophilized vials, prefilled syringes, and dry powder injections, backed by 35 approved ANDAs and 19 commercialized drug products in the United States.
  • Complex Biologics Integrated contract development solutions for complex biologics combining flexible infrastructure, advanced technologies, and extensive capacity with process and analytics development and a dedicated team for tech transfer and scale-ups.
  • Soft Gelatin Capsules High-volume contract manufacturing of soft gelatin capsules producing up to 2.4 billion capsules annually in multiple formats and various shapes and sizes, using rapid and efficient production processes for high-quality softgel products.

Quantifiable outcome

  • 35 approved Abbreviated New Drug Applications (ANDAs) in the United States
  • +3 more outcomes

Companies that use Stelis Biopharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Stelis Biopharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Stelis Biopharma partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Stelis Biopharma competitors and assessment

Company assessment

Direct peers

  • Piramal Pharma Solutions: India-headquartered CDMO offering sterile injectables, drug-device combinations, and biologics manufacturing with global regulatory footprint. Closely comparable to OneSource in modality mix, customer base (US generic and innovator sponsors), and integrated CDMO positioning.
  • Syngene International: Bengaluru-based contract research, development and manufacturing organization serving global pharma with biologics manufacturing capabilities. Comparable as an India-headquartered, publicly listed CDMO with similar enterprise customer base.
  • Jubilant Pharmova: Indian integrated pharma and CDMO with sterile injectables, APIs, and biologics capabilities. Comparable as a domestic competitor in similar dosage forms and end-to-end development-to-commercial services for global sponsors.
  • Suven Pharmaceuticals: Indian CDMO focused on complex APIs and contract development/manufacturing for global pharma. Comparable as an India-based, publicly listed mid-sized CDMO serving innovator and generic sponsors with regulated manufacturing capabilities.
  • Neuland Laboratories: India-based CDMO specializing in APIs and peptide manufacturing with US FDA-approved facilities. Comparable as a smaller Indian publicly listed CDMO competing for similar pharma sponsor outsourcing contracts.

Broad incumbents

  • Samsung Biologics: South Korea-based pure-play biologics CDMO with very large single-site mammalian cell culture capacity. Comparable in biologics CDMO segment and as a major single-facility operator, though focused exclusively on biologics rather than OneSource's multimodal mix.
  • Lonza Group: Swiss-based global CDMO leader in biologics, cell and gene therapy, and small molecule manufacturing. Comparable as a broad incumbent with overlapping biologics and fill-finish capabilities, though at much larger scale and across multiple sites.
  • WuXi AppTec / WuXi STA: China-based global CRO/CDMO with substantial small molecule, biologics, and sterile injectable capacity. Comparable as a broad incumbent in integrated CDMO services, though operating at significantly larger scale.
  • Catalent: Global CDMO leader in softgel, sterile injectables, and drug-device combinations, now owned by Novo Holdings. Comparable as a broader incumbent offering many of the same modalities at significantly larger scale across multiple geographies.

Regional players

  • Aurobindo Pharma: India-based vertically integrated generic pharma manufacturer with significant US ANDA approvals and injectable manufacturing. Comparable as a domestic competitor with similar US generic commercialized product footprint, though primarily a product company rather than pure CDMO.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Stelis Biopharma social profiles

Digital presence

Stelis Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stelis Biopharma leadership team

Management profile

Number of profiles

Stelis Biopharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stelis Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stelis Biopharma

What does Stelis Biopharma do?

Stelis Biopharma, operating through its brand OneSource, is a multimodal specialty pharmaceutical and biologics Contract Development and Manufacturing Organization (CDMO) delivering end-to-end drug development and manufacturing across four capability platforms: drug-device combinations (prefilled syringes, pen injectors, autoinjectors), sterile injectables (liquids, lyophilized vials, prefilled syringes, dry powder injections), complex biologics (process and analytics development, tech transfer and scale-ups), and soft gelatin capsules (up to 2.4 billion capsules annually). Services are delivered under a single-contract model from one state-of-the-art, regulatory-approved facility to reduce clients' operational interfaces across the product lifecycle.

When was Stelis Biopharma founded?

Stelis Biopharma was founded in -1. It employs 251 to 500 people.

Where is Stelis Biopharma based?

Stelis Biopharma is headquartered in Not specified in source, India, in the Asia region.

How does Stelis Biopharma make money?

One revenue line is on record: contract Manufacturing Services.

Who are Stelis Biopharma's main competitors?

Direct peers on record are Piramal Pharma Solutions, Syngene International, Jubilant Pharmova, Suven Pharmaceuticals and Neuland Laboratories. Broad incumbents are Samsung Biologics, Lonza Group, WuXi AppTec / WuXi STA and Catalent. Aurobindo Pharma is listed as a regional player.

Does Stelis Biopharma have an API?

No public API is recorded for Stelis Biopharma.

What industry is Stelis Biopharma in?

Stelis Biopharma's product category is Pharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SahiONESOURCE Specialty Pharma Signs Strategic Manufacturing Deal With Formycon AG For 5 Global BiosimilarsONESOURCE Specialty Pharma has entered a long-term strategic partnership with Germany-based Formycon AG to provide CDMO services for 5 biosimilar molecules, with manufacturing to be conducted at ONESOURCE's Bengaluru facility. The deal is expected to drive a 15% increase in capacity utilization over the next 18 months and validates ONESOURCE's consolidated biologics manufacturing infrastructure following the merger of Stelis Biopharma and Steriscience. The partnership positions ONESOURCE to capture growth from the global biosimilar market projected to reach $75 billion by 2030, as several blockbuster biologics face patent expiries in the 2026–2028 window.ScanXOneSource Q4 Revenue Jumps 47% to INR4,282 MillionOneSource Specialty Pharma Limited reported Q4FY26 revenue of INR4,282 million, representing a 47% sequential increase driven by commercial shipments of drug device combinations and the launch of generic Semaglutide in India. EBITDA surged over 5x sequentially to INR919 million with adjusted PAT of INR390 million, recovering from a loss in the previous quarter, though full-year FY26 revenue declined 2% year-on-year to INR14,216 million due to earlier approval delays. The company reaffirmed its FY28 guidance targeting US$400 million in organic revenue with approximately 40% EBITDA margins, while deferring a previously announced acquisition of the injectables business from Steriscience and Brooks citing valuation concerns.Business TodayBiologics will be a major contributor to our growth, says Syngene CEO Jonathan HuntSyngene International plans to launch its biologics facility, Unit 3, in Bengaluru by late 2024, which will triple its biomanufacturing capacity. CEO Jonathan Hunt said biologics will be a major growth contributor, with expansion capacity in Bangalore and a recent acquisition of a manufacturing site from Stelis Biopharma.BusinessLineStrides Pharma arm raises $195 million through series B, C fundingStelis Biopharma, the biotech arm of Strides Pharma Science, has raised $195 million through Series B and C funding rounds to repay debt and fund general corporate purposes. The investment values Stelis at $350 million post-money, with proceeds allocated for completing its Contract Development and Manufacturing Organisation (CDMO) capabilities and accelerating vaccine infrastructure. The transaction is expected to close in 12 months following necessary shareholder approvals.The Pharma LetterBRIEF—Sputnik V vaccine production contracts with 3 Indian firmsThe Russian Direct Investment Fund signed production contracts with three Indian manufacturers for over 300 million doses of the Sputnik V vaccine in seven days. The contracts secure capacity for more than 700 million people across 10 countries, with Virchow Biotech, Stelis Biopharma, and Gland Pharma involved. Dr Reddy's Laboratories also has a distribution tie-up.YourStory[Funding alert] Stelis concludes $195 M Series B, C fund raiseStelis Biopharma concluded its Series B and C funding round for $195 million, with a post-money valuation of $350 million. The round was led by TPG Growth, and Strides Pharma Science plans to demerge and list Stelis on a standalone basis.Business StandardStrides dips 6% from high on profit booking as Aditya Puri joins as advisorStrides Pharma shares fell 3% to Rs 939 on Friday after Aditya Puri joined as advisor to the group and director of Stelis Biopharma. The stock had hit a 52-week high of Rs 1,000 intra-day, and has risen 130% in six months. Puri, former HDFC Bank CEO, said he looks forward to building world-class institutions.GlobeNewswireStelis Biopharma and Oncobiologics to Unveil Bio2Source CDMO Offering at BIO 2018Stelis Biopharma and Oncobiologics will unveil a joint CDMO offering, Bio2Source, at BIO 2018 in Boston. Oncobiologics will provide mammalian cell process development and bulk drug manufacturing, while Stelis offers microbial development, fill-finish, and lyophilization services. The initiative is facilitated by strategic investor GMS Tenshi.PR NewswireMerck und Stelis Biopharma eröffnen erstes Gemeinschaftslabor für den Scale-up von BioprozessenMerck and Stelis Biopharma opened a joint scale-up lab in Bengaluru, India, to provide end-to-end solutions for bioprocess development and manufacturing. The lab aims to accelerate clinical trial supply and bridge the gap between lab and production scale. The collaboration combines Stelis's high-yield process development with Merck's biotechnological expertise.PR NewswireMerck und Stelis Biopharma eröffnen erstes Gemeinschaftslabor für den Scale-up von BioprozessenMerck and Stelis Biopharma have opened a joint process scale-up laboratory in Bengaluru, India, to provide end-to-end bioprocessing solutions for preclinical, clinical, and commercial stages. The facility combines Stelis's bioprocess development expertise with Merck's technological capabilities to accelerate the transfer of optimized processes from lab to production scale. This collaboration aims to enhance reliability and cost-efficiency for customers developing biopharmaceutical candidates.